Spots Global Cancer Trial Database for Combination Immunotherapy Targeting Sarcomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combination Immunotherapy Targeting Sarcomas

Official Title: Safety and Efficacy Evaluation of a Combination Immunotherapy Targeting Sarcomas

Study ID: NCT04433221

Conditions

Sarcoma

Osteoid Sarcoma

Ewing Sarcoma

Interventions

Multiple sarcoma-specific CAR-T cells and sarcoma vaccines

Study Description

Brief Summary: The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.

Detailed Description: Patients with late staged and/or recurrent sarcoma have poor prognosis despite complex multimodal therapy. Therefore, innovative interventions are needed. Sarcoma is known to express increased levels of surface antigens that can be targeted by CAR-T cells. In addition, studies have shown that low dose chemotherapy such as doxorubicin may modulate surface PD-L1 level and enhance immunotherapy effects. This study will combine multiple CAR T cells with low dose chemotherapy to treat sarcoma, and followed by maintenance sarcoma vaccines. The purpose of this clinical trial will assess the feasibility, safety, efficacy and side effects of this combination therapy in patients who have sarcoma that is relapsed or late staged.